Observational cohorts have emerged as important resources to study course and prognosis of chronic disease, and also facilitate phenotype definition for genetic studies. We describe the development and accomplishments of the PsA cohort at the University of Toronto as an example of an observational cohort that has allowed the description of disease manifestations, course and prognosis of PsA. We also describe the development of an international collaboration based on this cohort, which will further be used to study the incidence, prevalence and predictive factors for the development of PsA among patients with psoriasis.
Introduction
Rheumatic disorders are complex conditions characterized by a variety of clinical manifestations and disease courses in different patients with the same condition. The best way to understand the course and prognosis of these patients is through observational cohort studies. Such studies are dependent on prospective collection of data on a large number of patients followed according to the standard protocols. The protocols typically include detailed information on clinical features, laboratory assessments and radiological evaluation. More recently genetic information has been collected. As in basic laboratory research, an observational cohort study must be scientifically sound. Thus, the methods used in clinical evaluations must be accurate, standardized and reliable. Observational cohort studies provide an opportunity to identify new clinical features, describe clinical course and outcome, including therapeutic responses in the observed patient. Such studies have been facilitated by computer technology that allows tracking of a large number of patients as well as the analysis of large amounts of data [1] .
Observational cohort studies
The term cohort is used to describe a group of people who have something in common when they are first assembled. A cohort may be established based on a particular diagnosis, and individuals may be recruited either at the time of diagnosis or any time in the course of their disease. To be meaningful, cohorts should be observed over a prolonged period of time and should provide as complete a follow-up as possible. Within a cohort study, a cross-sectional design may be used to describe a certain disease manifestation, while a case-control design may be used to determine predictors for a particular manifestation or response to therapy. Using longitudinal follow-up, cohort studies may be used to describe disease course and record long-term complications of disease and its therapy. Within a cohort, a nested case-control design may be used to detect associations between course and drug therapy, predictors of response or resistance to therapy, as well as drug toxicity. In addition, cohort studies help to understand disease pathogenesis and provide insight into the mechanisms of disease progression. Information derived from such studies may help to design future clinical trials. The strengths of a cohort study are that it has a large number of patients with detailed clinical information over a long period of time. Thus, it is superior to a randomized controlled trial where selected individuals are included, who are followed for a short period of time. The inclusion criteria are usually restrictive such that not all individuals with the condition are included. Observational cohorts are distinguished from registries by the amount of information collected and the careful follow-up of patients. Certain requirements are necessary before a longitudinal data set can be used in the study of prognosis. There must be demonstrable internal and external validity of the cohort collected. The patients should be representative of the population from which they are drawn such that they can be considered a random sample to avoid selection bias. The methods of observation must be clearly defined and the measurement tools must be valid and reliable. Complete follow-up is important to avoid information bias. Confounding factors such as time and intervention need to be considered, and may be overcome by design and analysis.
Psoriatic arthritis
PsA is an example of a complex rheumatic disease [2] . It is defined as an inflammatory arthritis associated with psoriasis, usually seronegative for RF. While the majority of the patients have psoriasis either before or concurrently with the onset of arthritis, some 15% of the patients present with arthritis before the recognition of psoriasis. Specific clinical features associated with PsA allow the diagnosis to be made. These include the involvement of the DIP joints, asymmetric distribution of the arthritis, which often affects all three joints of the same digit as opposed to similar joints in both hands or both feet as seen in RA. Dactylitis, or inflammation of the whole digit, occurs in almost half the patients, and enthesitis, inflammation of the insertion of tendons or ligaments into bone, occurs in at least one-third of the patients. Axial disease occurs in about half the patients with PsA. In addition, the majority of patients with PsA have nail lesions, which may precede the development of skin psoriasis. Patients with PsA have a variable course and prognosis, with at least 20% of the patients having a severe rapidly destructive form of arthritis (arthritis mutilans) and perhaps as many as 20% who never develop any joint destruction [3] . PsA was considered a rare and mild disease until the past few decades.
The University of Toronto Psoriatic Arthritis Program
The University of Toronto PsA Clinic at the Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital is an example of an observational cohort study [3] . The PsA Clinic was established in 1978 to study the course and prognosis of patients with PsA. At that time, PsA was considered an uncommon and mild disease. However, over a period of 4 months in 1977, upon consulting at the Psoriasis Education and Research Centre at Women's College Hospital in Toronto, it became clear to the senior author (D.D.G.) that the disease was much more serious, with some patients rapidly developing joint damage. It was recognized that in order to confirm these anecdotal clinical observations, a prospective cohort of a large number of patients diagnosed with PsA had to be established. Subsequently, patients with psoriasis who had inflammatory arthritis and were diagnosed to have PsA based on modified Moll and Wright criteria were recruited to participate in the cohort [3] . Referrals are usually made by family physicians, dermatologists or rheumatologists. Most patients reside in the Greater Toronto area and surrounding regions of Southern Ontario, Canada. The ethnic diversity of the cohort reflects that seen in this region of Canada over the period of cohort accrual. Currently, 87% are of European, 5% are of South Asian and 2.5% are of Chinese ethnicity and the rest belong to other or mixed ethnicity. All patients sign an informed consent according to the Declaration of Helsinki, agreeing to participate in the longitudinal follow-up, have their information stored in our computerized database, and have their DNA stored and analysed for studies performed by our team. Studies performed at the PsA Clinic have been approved by the University Health Network Research Ethics Board.
Patients are followed at 6-to 12-month intervals according to a standardized protocol that includes clinical and laboratory information at each visit; patient-derived instruments such as the HAQ, Medical Outcome Survey Short Form 36 (SF-36) and a fatigue scale once a year; and radiographic evaluation every 2 years. All data are tracked in an Oracle database. There are now 1067 patients registered in the database ( Table 1 ). The methods of evaluation and measurements performed in the clinic are reliable. Thus, we have shown that the physicians attending the clinic reliably assess joint activity and damage [4] . The radiographic scoring method used, a modification of the Steinbrocker technique, was also proved reliable and sensitive to progression of damage over time [5] . The patient-derived questionnaires [HAQ, SF-36 and Functional Assessment of Chronic Illness Therapy (FACIT) fatigue] have also been validated in our clinic [6] [7] [8] .
We demonstrated that there was no systematic bias in our clinic. It was suggested that we recruited patients with more severe disease into our original cohort as physicians would refer patients with more severe disease. However, patients registered in the first 5 years and those registered in the second 5 years had similar characteristics at presentation to clinic [9] . With regard to follow-up, there did not appear to be a systematic bias as patients followed for 5 years and those not followed for 5 years had similar characteristics at presentation. Moreover, patients lost to follow-up and those followed regularly had similar disease characteristics at presentation.
Nonetheless, we have tried to minimize loss to follow-up in the clinic. To minimize loss to follow-up, we have used a number of methods. First, we try and call patients who miss their scheduled clinic appointments immediately and rebook their appointment. Secondly, we carry out a loss to follow-up study every 2 years at which time we capture patients who have not shown up within 18 months of the study. Of the 1066 patients currently registered in our cohort, 125 have died. The overall proportion lost to follow-up is 14%. Of those, 89 patients are truly lost to follow-up, 28 have declined further participation in the clinic and 33 have not yet made follow-up appointments, and may reduce the proportion of those lost to follow-up once they are reviewed.
What have we learnt from this careful follow-up?
The PsA database has allowed us to demonstrate that PsA is more severe than previously thought. We found that 20% of the patients have severe disease with deformities, radiological damage and functional disability [3] . Clinical damage progresses over time such that 55% of the patients who have been observed for >10 years have >5 clinically damaged joints [10] . We have also been able to identify predictors for progression of clinical damage, defined by the presence of limitation of movement that is >20% of the range but not due to effusion, deformities, flail or fused joints, or joints that had undergone surgery. This concept was unique to our clinic when we first started, and was developed since assessment of clinical damage can be performed at each patient encounter, while radiographs are performed at less frequent intervals due to cost and radiation exposure. Patients with 55 swollen joints at presentation to clinic, those who have been treated with a higher level of medication and with corticosteroid therapy are at increased risk of progression of clinical damage [11] . The number of actively inflamed joints at each visit is predictive of progression of clinical damage, as is the degree of damage already accrued [12] . The same is true for radiological damage. Both the total number of actively inflamed joints (tender and swollen), and the number of swollen joints, as well as the number of clinically damaged joints predict progression of both clinical and radiological damage [13] . On the other hand, patients who sustain remission (no actively inflamed joints for at least 12 months) have a lower number of actively inflamed joints than those who do not [14] . We determined that 17.6% of our patients sustained remission, which lasted for 2.6 years on average. However, 52% of the patients flared and only 6% sustained true remission. We have also shown that 34% of our patients achieve sustained minimal disease activity (MDA) for >12 months, with an average duration of 28 months. Low ESR and oligoarthritis were predictors of achieving MDA. Patients achieving MDA have significantly less joint damage progression than those who do not achieve MDA [15] . Using carefully collected clinical data, we have also shown that patients with PsA are at increased risk of cardiovascular morbidities compared with the general population [16] . Factors associated with cardiovascular disease included diabetes, hyperlipidaemia and high Psoriasis Area and Severity Index (PASI) scores. Thus, in addition to known risk factors for cardiovascular disease, severe psoriasis is an important predictor in patients with PsA. We have also shown that although 10.2% of patients in our cohort developed cancer, the incidence of malignancy in this large PsA cohort did not differ from that in the general population [17] .
Through the database we found that patients with PsA were at an increased risk of death, and that while causes of death were similar to those observed in the general population, the increased mortality risk is predicted by disease severity at presentation [18, 19] . More recently, we found that survival has improved over the past two decades [20] . We have also determined that patients with PsA have a reduced health-related quality of life, and that their satisfaction with health is related to features other than the disease process [21] . Patients with PsA suffer from fatigue that is related to disease manifestations [22] .
This longitudinal observational study has also provided information on disease features. Dactylitis occurred in almost half the patients at some point in their disease, and was associated with more erosive change [23] . Axial disease occurred in 25% of the patients at presentation, but accrued over the course of the disease in many more [24, 25] . We also showed that in patients who do not have axial disease at first clinic visit, 15% would develop axial PsA (AxPsA) at 10 years of follow-up. Severe peripheral arthritis and HLA-B*27 are risk factors for AxPsA [26] . We have also documented the frequency of laboratory abnormalities such as hyperuricaemia [27] and presence of autoantibodies [28] .
The database provided important information on drug responses. We found that MTX was not helpful in preventing progression of joint damage, although it was better when used earlier in the disease course and at a higher dose [29, 30] . We have also shown that folate pathway gene polymorphisms may play a role in MTX efficacy and liver toxicity [31] . We also found that chloroquine, gold, SSZ and AZA were not particularly helpful in our patients [32] [33] [34] [35] . We have shown that in refractory PsA, infliximab led to a marked improvement in psoriasis but modest response in joint disease. Toxicity and rate of treatment termination was high [36] . Our patients have also had an opportunity to participate in most of the large multicentre clinical trials of biologic agents in PsA.
From bedside to bench and back again
Genetic factors play an important role in the aetiology of both psoriasis and PsA [37] . The PsA Clinic is associated with a research laboratory, which over the years has concentrated on genetic studies. Proper phenotyping is key to genetic analysis; thus, our cohort is an important resource for conducting genetic analysis on disease susceptibility and expression. We have demonstrated that PsA has a strong genetic component since the recurrence risk ratio in siblings with PsA is high [38] . We have also shown that there is excessive paternal transmission in PsA, indicating a role of epigenetic factors in disease susceptibility [39] . Using the careful phenotype definition obtained through our database, we were able to determine that HLA antigens were more strongly associated with progression of clinical damage than the clinical features [40, 41] . We were also able to confirm the role of HLA haplotypes in the development of PsA in siblings [42] . Patients with HLA-Cw*0602 had an earlier age of onset of psoriasis [43] . Using our data set, we identified novel associations between PsA and killer cell immunoglobulinlike receptor (KIR) genes. We found that the activating KIRs 2DS1 and 2DS2 were associated with PsA when the corresponding ligands to their inhibitory counterparts were not present [44, 45] . We were also able to detect associations of PsA with several candidate genes including TNF-a [46] , SEEK1 [47] , IL-1 gene cluster [48] and IL-23R [49] . Combining our longitudinal data and genetic markers, we demonstrated that the IL-4 I50V is a marker for erosive disease in PsA [50] . We participated in a validation study for a genome-wide association study in psoriasis and helped to confirm the role of several candidate loci in the aetiology of psoriasis [51] .
Thus, a large number of studies have been completed using data collected from our PsA Clinic. To date, there are 95 original research papers and 25 review articles from the cohort cited in PubMed (date last accessed 4 June 2010). In addition, there are 29 invited publications, 31 book chapters and 1 book based on the data from the cohort.
Psoriasis database
Our longitudinal cohort of PsA patients confirmed that most patients developed PsA after the onset of cutaneous psoriasis. However, the mean disease duration at clinic entry is 7 years; thus, most patients have well-established disease. Genetic studies conducted by ourselves and others have also detected genes associated with PsA. However, it is often difficult to differentiate markers associated with psoriasis from those associated with PsA. In order to take advantage of genetic markers to enable us to identify patients with PsA early, as well as to study early events in PsA, we have now established a cohort of patients with psoriasis without arthritis who are followed prospectively for the development of PsA. This cohort currently has 438 subjects ( Table 1) . So far 5% of the patients have developed PsA within 4 years of follow-up. As this cohort is further enhanced with more patients and longer follow-up, we shall be in a position to compare genetic and clinical factors that differentiate PsA from patients with cutaneous psoriasis alone. In fact, pilot studies on biomarkers and peripheral blood gene expression profiles have provided interesting results [52, 53] . Moreover, we shall be able to study early events in PsA by investigating genomic, transcriptomic, proteomic, imaging and clinical markers in those patients with cutaneous psoriasis who develop PsA on follow-up.
International Psoriasis and Arthritis Research Team
Over the past decade, it was realized that genetic studies especially genome-wide association studies require large number of well-phenotyped patients. Results from one cohort need to be replicated in independent cohorts. Prognostic studies also need validation. We have therefore established collaboration among several groups from Canada and the USA. The IPART aims to recruit 1500 patients each with PsA and psoriasis and follow them longitudinally using standard protocols developed at the University of Toronto PsA Clinic. All data are tracked on a web-based database. We aim to conduct genetic studies on susceptibility and prognosis using carefully phenotyped patients with psoriasis and PsA, as well as to identify factors associated with arthritis in patients with psoriasis. Other areas of interest include disease progression, severity and comorbidities. Published data from such large, multicentre PsA cohorts are not available. Therefore, comparison of the disease characteristics with cohorts elsewhere is difficult. However, recently data on PsA patients in the Consortium of Rheumatology Researchers of North America (CORRONA) database were published as an abstract [54] . Table 2 provides a comparison of patients in the two databases. Patients in the IPART database are younger and have shorter disease duration, but seem to have more severe disease and less exposure to anti-TNF agents. However, such a comparison is preliminary and a formal study comparing the two North American cohorts is warranted.
Challenges ahead
The University of Toronto PsA cohort has helped us understand PsA better. Newer cohorts of psoriasis and IPART will ultimately help us understand disease susceptibility and prognosis of both psoriasis and PsA. However, recruitment and management of such open dynamic cohorts present with unique challenges. It is important to assess patients reliably. While clinical assessments have been proved reliable, radiographic scoring of peripheral and axial joints needs to be standardized across all sites. The collected data are tracked in a webbased database (www.datazoomweb.com/apps/cihr_ parti.aspx). Programs to detect errors in certain variables are in place. To avoid selection bias, complete follow-up is necessary. The database is programmed to remind research assistants when patients are expected for follow-up. At the PsA Clinic, we have a newsletter that is distributed to all patients once a year and informs them of outcomes of our studies and new developments in the field. We also conduct patient-education symposia once a year. Patients are encouraged to continue follow-up. Patient satisfaction with the process is periodically assessed using questionnaires. To enhance participation by investigators, the database is set up to provide summary scores or a graphical representation of joint counts, PASI scores and damage progression. We also plan to provide a summary that may be sent to the patient's primary care provider along with the consultation report.
Analyses of data generated through the project also pose significant challenges. Advances in statistical methods and computer technology have facilitated data analysis and interpretation. However, the team requires biostatisticians with expertise in the analysis of such data. Both the PsA Program and IPART include biostatisticians as members of the team.
Most importantly, longitudinal observational cohort studies require a significant amount of financial and human resources. The database must be maintained for which research assistants, programmers and database managers are needed. Thus, for a database of chronic life-long disease such as psoriasis and PsA to achieve full potential, long-term financial commitment from research agencies, contributions from individual donors as well as pharmaceutical companies will be required on a long-term basis. This remains a major challenge as many Values are represented as mean (S.D.) unless otherwise specified.
www.rheumatology.oxfordjournals.org funding agencies prefer to fund hypothesis-driven research rather than database research, and each individual grant does not necessarily allow for the infrastructure support necessary to carry out the research. To conclude, we have gained significant knowledge on the course and prognosis of PsA from the University of Toronto PsA Clinic. PsA is a heterogeneous disease; results from observational cohorts can clarify features of the different subtypes and be of help in genetic studies. Due to the size of the cohorts and length of observation, our analyses have the power to lead to conclusions that contribute to the reappraisal of several aspects of PsA. However, the relationship between psoriasis and PsA is still unclear. It is hoped that once the IPART database on psoriasis and PsA matures, further insight into psoriasis and PsA will be gained and previous results obtained from a large single-centre cohort will be validated. Success of this project poses methodological and logistical challenges, which will have to be overcome.
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. Longitudinal cohorts are important resources to study course and prognosis of chronic disease. . Longitudinal cohorts facilitate phenotype definition for genetic studies. . Information on genetics, clinical features, course and prognosis of PsA was generated from the University of Toronto Psoriatic Arthritis Program.
